EyePoint Pharmaceuticals (STU:PV3B) Debt-to-Asset

: 0.01 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

EyePoint Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. EyePoint Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4.50 Mil. EyePoint Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €325.70 Mil. EyePoint Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

EyePoint Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for EyePoint Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.69

0.45

0.15

0.25

0.01

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.25	0.26	0.04	0.04	0.01

Competitive Comparison

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Debt-to-Asset falls into.

EyePoint Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

EyePoint Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	4.499)	/	325.704
	=	0.01

EyePoint Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	4.499)	/	325.704
	=	0.01

EyePoint Pharmaceuticals (STU:PV3B) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

EyePoint Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines